April 2018

New Product - Olumiant

Olumiant (baricitinib) is a selective and reversible inhibitor of Janus kinases (JAK) 1 and 2, reducing the phosphorylation and activation of signal transducers and activators of transcription (STATs). Olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults who have responded inadequately, or who are intolerant, to one or more DMARDs. Olumiant can be taken as monotherapy or in combination with cDMARDs, including methotrexate. Olumiant must not be used in combination with bDMARDs. Olumiant 4 mg tablets are available in packs of 28.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au